Qualigen

    OverviewSuggest Edit

    Qualigen is a biotechnology company. It is focused on the development and commercialization of therapeutic products for the treatment of cancer and infectious diseases, as well as the expansion of FastPack, its diagnostic platform.
    TypePrivate
    Founded1996
    HQCarlsbad, CA, US
    Websitequaligeninc.com
    Employee Ratings4.5

    Latest Updates

    Employees (est.) (Apr 2020)4
    Cybersecurity ratingBMore
    Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
    Banner background

    Key People/Management at Qualigen

    Michael S. Poirier

    Michael S. Poirier

    President, CEO and Chairman
    Kurt H. Kruger

    Kurt H. Kruger

    Director
    Christopher L. Lotz

    Christopher L. Lotz

    Chief Financial Officer
    Matthew E. Korenberg

    Matthew E. Korenberg

    Director
    Amy S. Broidrick

    Amy S. Broidrick

    Executive Vice President, Chief Strategy Officer
    Ira E. Ritter

    Ira E. Ritter

    Director
    Show more

    Qualigen Office Locations

    Qualigen has an office in Carlsbad
    Carlsbad, CA, US (HQ)
    2042 Corte Del Nogal suite b
    Show all (1)

    Qualigen Financials and Metrics

    Summary Metrics

    Founding Date

    1996

    Qualigen Cybersecurity Score

    Cybersecurity ratingPremium dataset

    B

    86/100

    SecurityScorecard logo

    Qualigen Online and Social Media Presence

    Embed Graph

    Qualigen News and Updates

    Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

    CARLSBAD, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will present a…

    Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    CARLSBAD, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will present a…

    Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results

    CARLSBAD, Calif.,, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces its intention to prioritize its focus to its oncology pipeline that includes QN-247 and RAS-F. These plans follow feedback the Company received from the United States Food and Drug Admin…

    Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19

    CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today the submission of an Investigational New Drug (IND) application to the U.…

    Qualigen Therapeutics Announces Inclusion in Russell Microcap® Index

    CARLSBAD, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that according to a preliminary list of additions posted June 4 it will b…

    Qualigen Therapeutics, Inc. to Present at the LD Micro Invitational XI Conference

    CARLSBAD, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that its CEO and Chairman Michael Poirier will present and participate at…
    Show more

    Qualigen Blogs

    Associate Director Program Management

    Reporting to VP, Chief Operating Officer Location Qualigen Therapeutics, Inc.2042 Corte del Nogal, Suite BCarlsbad, California 92011 Number of Reports Number of Direct Reports: 0, Number of Indirect Reports: 0 Purpose of the Role Qualigen Therapeutics, Inc. is a NASDAQ-listed biotechnology company d…

    Senior Business Development Analyst

    Location Qualigen Therapeutics, Inc.2042 Corte del Nogal, Suite BCarlsbad, California 92011 Purpose of the Role Qualigen Therapeutics, Inc. is a publicly traded biotechnology company developing novel therapeutics for the treatment of cancer and infectious diseases, as well as expanding its FDA-appro…
    Show more

    Qualigen Frequently Asked Questions

    • When was Qualigen founded?

      Qualigen was founded in 1996.

    • Who are Qualigen key executives?

      Qualigen's key executives are Michael S. Poirier, Kurt H. Kruger and Christopher L. Lotz.

    • How many employees does Qualigen have?

      Qualigen has 4 employees.

    • Who are Qualigen competitors?

      Competitors of Qualigen include Jiangsu Hansoh Pharmaceutical Group, 3sbio and Kyowa Kirin.

    • Where is Qualigen headquarters?

      Qualigen headquarters is located at 2042 Corte Del Nogal suite b, Carlsbad.

    • Where are Qualigen offices?

      Qualigen has an office in Carlsbad.

    • How many offices does Qualigen have?

      Qualigen has 1 office.